CD38 and plasma cell myeloma: Multiple myeloma patients receiving bortezomib, thalidomide and DEX with or without the anti‐CD38 monoclonal antibody, daratumumab, had no changes in DC populations in the absence of daratumumab during 12 weeks of treatment.17